Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS · Delayed Price · Currency is USD
0.1601
-0.0054 (-3.26%)
At close: Sep 18, 2026

Northwest Biotherapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
273358364822830663
Market Cap Growth
-27.46%-1.53%-55.72%-1.00%25.14%-47.13%
Enterprise Value
339444435881865686
Last Close Price
0.160.230.270.700.780.70

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-----3.70
PS Ratio
125.67260.08263.35425.38493.23660.04
PB Ratio
-7.85-7.53-4.61-17.47-7.90-5.35

EV Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EV/Sales Ratio
156.15322.41314.92455.93513.96682.10

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
-1.62-1.36-0.85-0.97-0.25-0.31
Net Debt / Equity Ratio
-1.61-1.30-0.83-0.92-0.18-0.18
Net Debt / EBITDA Ratio
-1.17-1.07-1.01-0.80-0.29-0.43
Net Debt / FCF Ratio
-1.12-1.33-1.12-0.76-0.35-0.51
Asset Turnover
0.040.030.050.070.050.03
Quick Ratio
0.010.030.030.050.060.11
Current Ratio
0.040.060.060.090.080.13
Return on Assets (ROA)
-59.64%-69.33%-152.28%-117.23%-117.48%-90.17%
Return on Capital Employed (ROCE)
-1944.00%575.50%160.10%320.10%71.00%56.30%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-14.24%-16.79%-23.02%-7.62%-12.65%27.00%
FCF Yield
-18.23%-12.91%-15.95%-6.94%-6.71%-6.68%
Buyback Yield / Dilution
-16.62%-17.26%-10.99%-10.17%-0.79%-38.99%